| Literature DB >> 33528655 |
Christof Iking-Konert1, Christof Specker2, Klaus Krüger3, Hendrik Schulze-Koops4, Peer Aries5.
Abstract
On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.Entities:
Keywords: COVID-19; SARS-CoV-2; STIKO recommandation; Vaccination; mRNA vaccination
Mesh:
Substances:
Year: 2021 PMID: 33528655 PMCID: PMC7852047 DOI: 10.1007/s00393-021-00966-9
Source DB: PubMed Journal: Z Rheumatol ISSN: 0340-1855 Impact factor: 1.372